Scotoma analysis of 10–2 visual field testing with a red target in screening for hydroxychloroquine retinopathy

Clinical Ophthalmology

Volumn 9, Issue , 2015, Pages 1499-1509

  Browning, David J ^a   Lee, Chong ^a  

^a Department of Ophthalmology Charlotte Eye Ear Nose and Throat Associates ^*  (United States)

Author keywords

Ancillary testing; Ideal body weight; Red test object; Toxicity

Indexed keywords

CHLOROQUINE; HYDROXYCHLOROQUINE;

ADULT; AGE DISTRIBUTION; AGED; ARTICLE; AUTOIMMUNE DISEASE; CLINICAL ARTICLE; CONNECTIVE TISSUE DISEASE; CONTROLLED STUDY; DOSE CALCULATION; DRUG INDUCED DISEASE; DRUG WITHDRAWAL; ELECTRORETINOGRAPHY; EYE FIXATION; FEMALE; HIGH RISK POPULATION; HUMAN; HYDROXYCHLOROQUINE RETINOPATHY; IMAGE ANALYSIS; MEDICAL RECORD REVIEW; MULTIFOCAL ELECTRORETINOGRAPHY; OUTCOME ASSESSMENT; PERIMETRY; RETINOPATHY; RETROSPECTIVE STUDY; RHEUMATOID ARTHRITIS; SCOTOMA; SPECTRAL DOMAIN OPTICAL COHERENCE TOMOGRAPHY; SYSTEMIC LUPUS ERYTHEMATOSUS; TREATMENT DURATION;

EID: 84940181363     PISSN: 11775467     EISSN: 11775483     Source Type: Journal    
DOI: 10.2147/OPTH.S87850     Document Type: Article

References (28)

1. Browning DJ. Hydroxychloroquine and Chloroquine Retinopathy. New York: Springer; 2014.
2. Johnson MW, Vine AK. Hydroxychloroquine therapy in massive total doses without retinal toxicity. Am J Ophthalmol. 1987;104:139-144.
3. Mititelu M, Wong BJ, Brenner M, Bryar PJ, Jampol LM, Fawzi AA. Progression of hydroxychloroquine toxic effects after drug therapy cessation. new evidence from multimodal imaging. JAMA Ophthalmol. 2013;131:1187-1197.
4. Xiaoyun MA, Dongyi HE, Linping HE. Assessing chloroquine toxicity in RA patients using retinal nerve fiber layer thickness, multifocal electroretinography and visual field test. Br J Ophthalmol. 2010;94:1632-1636.
5. Lai TY, Chan WM, Li H, Lai RY, Lam DS. Multifocal electroretinographic changes in patients receiving hydroxychloroquine therapy. Am J Ophthalmol. 2005;140:794-807.
6. Lyons JS, Severns ML. Detection of early hydroxychloroquine retinal toxicity enhanced by ring ratio analysis of multifocal electroretinography. Am J Ophthalmol. 2007;143:801-809.
7. Chen E, Brown DM, Benz MS, et al. Spectral domain optical coherence tomography as an effective screening test for hydroxychloroquine retinopathy (the "flying saucer" sign). Clin Ophthalmol. 2010;4:1151-1158.
8. Kellner U, Renner AB, Tillack H. Fundus autofluorescence and mfERG for early detection of retinal alterations in patients using chloroquine/ hydroxychloroquine. Invest Ophthalmol Vis Sci. 2006;47:3531-3538.
9. Marmor MF, Kellner U, Lai TY, Lyons JS, Mieler WF; American Academy of Ophthalmology. Revised recommendations on screening for chloroquine and hydroxychloroquine retinopathy. Ophthalmology. 2011;118:415-422.
10. Browning DJ. Impact of the revised american academy of ophthalmology guidelines regarding hydroxychloroquine screening on actual practice. Am J Ophthalmol. 2013;155:418-428.e1.
11. Lyons JS, Severns ML. Using multifocal ERG ring ratios to detect and follow Plaquenil retinal toxicity: a review: Review of mfERG ring ratios in Plaquenil toxicity. Doc Ophthalmol. 2009;118:29-36.
12. Browning DJ, Lee C. Scotoma analysis of 10-2 visual field testing with a white target in screening for hydroxychloroquine retinopathy. Clin Ophthalmol. 2015;9:943-952.
13. Browning DJ. Hydroxychloroquine and chloroquine retinopathy: screening for drug toxicity. Am J Ophthalmol. 2002;133:649-656.
14. Browning DJ, Lee C, Rotberg D. The impact of different algorithms for ideal body weight on screening for hydroxychloroquine retinopathy in women. Clin Ophthalmol. 2014;8:1401-1407.
15. Browning DJ. Reply to defining ideal body weight. Am J Ophthalmol. 2002;134:935-936.
16. Rao HL, Yadav RK, Begum VU, et al. Role of visual field reliability indices in ruling out glaucoma. JAMA Ophthalmol. 2015;133:40-44.
17. Heijl A, Patell VM. Statpac. In: Essential Perimetry Third Edition. Dublin, California: Carl Zeiss Meditec, 2002:57-58.
18. Murdoch IE, Morris SS, Cousens SN. People and eyes: statistical approaches in ophthalmology. Br J Ophthalmol. 1998;82:971-973.
19. Yam JC, Kwok AK. Ocular toxicity of hydroxychloroquine. Hong Kong Med J. 2006;12:294-304.
20. Marmor MF, Chien FY, Johnson MW. Value of red targets and pattern deviation pots in visual field screening for hydroxychloroquine retinopathy. JAMA Ophthalmol. 2013;131:476-480.
21. Wolfe F, Marmor MF. Rates and predictors of hydroxychloroquine retinal toxicity in patients with rheumatoid arthritis and systemic lupus erythematosus. Arthritis Care Res (Hoboken). 2010;62:775-784.
22. Saunders LJ, Russell RA, Crabb DP. Measurement precision in a series of visual fields acquired by the standard and fast versions of the Swedish interactive thresholding algorithm: analysis of large-scale data from clinics. JAMA Ophthalmol. 2015;133:74-80.
23. Browning DJ, Lee C. The relative sensitivity and specificity of 10-2 visual fields, multifocal electroretinography, and spectral domain optical coherence tomography in detecting hydroxychloroquine and chloroquine retinopathy. Clin Ophthalmol. 2014;8:1389-1399.
24. Easterbrook M, Trope G. Value of Humprey perimetry in the detection of early chloroquine retinopathy. Lens Eye Toxic Res. 1989;6:255-268.
25. Anderson C, Blaha GR, Marx JL. Humphrey visual field findings in hydroxychloroquine toxicity. Eye (Lond). 2011;25:1535-1545.
26. Browning DJ, Lee C. Test-retest variability of multifocal electroretinography in normal volunteers and short-term variability in hydroxychloroquine users. Clin Ophthalmol. 2014;8:1467-1473.
27. Lai TY, Ngai JW, Chan WM, Lam DS. Visual field and multifocal electroretinography and their correlations in patients on hydroxychloroquine therapy. Doc Ophthalmol. 2006;112:177-187.
28. Tanga L, Centofanti M, Oddone F, et al. Retinal functional changes measured by frequency-doubling technology in patients treated with hydroxychloroquine. Graefes Arch Clin Exp Ophthalmol. 2011;249:715-721.